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Abstract
The present study examined the effect of milk phospholipids (milk-PL) on lipid metabolism and on other risk factors for CVD, in comparison with milk fat
(control) or soya phospholipids (soya-PL), respectively. Two double-blind parallel-group intervention trials were conducted in overweight or obese male
subjects. In the ﬁrst trial (trial 1), sixty-two men consumed milk enriched with either 2 g milk-PL or 2 g milk fat (control) for 8 weeks. In trial 2, ﬁfty-seven
men consumed milk enriched with either 3 g milk-PL or 2·8 g soya-PL for 7 weeks. In trial 1, milk-PL as compared with control reduced waist circum-
ference but did not affect plasma lipids (total, HDL- and LDL-cholesterol, total cholesterol:HDL-cholesterol ratio, TAG, phospholipids), apoB, apoA1,
glucose, insulin, insulin sensitivity index, C-reactive protein, IL-6, soluble intracellular adhesion molecule and total homocysteine (tHcy). Serum activities of
alanine transaminase and aspartate transaminase were not changed. Activity of γ-glutamyl transferase (GGT), a marker of fatty liver, increased in the con-
trol but not in the milk-PL group, with a signiﬁcant intervention effect. In trial 2, milk-PL as compared with soya-PL did not affect the above-mentioned
parameters, but decreased GGT. Subjects with the methylenetetrahydrofolate reductase mutations CT and TT had 11 % (P< 0·05) higher baseline tHcy
concentrations than those with the wild-type CC. However, genotype did not modulate the phospholipid intervention effect on tHcy. In conclusion, sup-
plementation with milk-PL as compared with control fat reduced waist circumference and, as compared with both control fat and soya-PL, GGT activity.
Key words: Milk phospholipids: Soya phospholipids: Plasma lipids: Human nutrition: CVD
A high cholesterol concentration, particularly in LDL, and a
low HDL-cholesterol (HDL-C) concentration are accepted
risk factors for CVD. Obesity, particularly abdominal obesity,
is an independent risk factor for CHD in middle-aged men(1,2).
Obesity promotes alterations in other intermediate risks such
as dyslipidaemia, glucose intolerance and inﬂammatory
state(2). Non-alcoholic fatty liver disease promoted by obesity
is also associated with an increased prevalence of CVD(3,4).
Phospholipids (PL) belong to the dietary components which
may affect cholesterol metabolism. They are polar lipids which
occur in all animal and plant membrane structures. The human
diet provides 2–8 g PL per d, which represents 1–10 % of total
fat intake. Foods with a high PL content include eggs, meats,
ﬁsh, grains and oilseeds. The most common PL in foods is
phosphatidylcholine (PC). Sphingomyelin (SM), a P-containing
sphingolipid, is solely present in animal food sources, i.e. in
eggs, meat and ﬁsh, and is ingested at a level of 0·3–0·4 g/d(5).
Previously mostly soya-PL (trivial name soyabean lecithin)
were tested in the course of animal and human feeding trials.
They are rich in PUFA, mainly linoleic acid. In animal studies
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soya-PL inhibited cholesterol absorption, decreased plasma
cholesterol and also liver lipids, and protected against the
development of atherosclerosis (for a review, see Cohn
et al.(5)). Small-size short-term human studies showed that
soya-PL may increase HDL-C(6) and apoA1(6,7).
Animal polar lipids differ from soya-PL in several aspects.
Only animal PL contain SM. Particularly their PC and SM
classes are rich in SFA. The majority of milk polar lipids,
mostly PL (milk-PL), are contained in the milk fat globule
membrane (MFGM)(8) and are closely associated with pro-
teins(9). In fact, animal-source PL or ‘saturated’ PL showed
high bioactivity. Milk-SM inhibited cholesterol absorption in
mice more than egg-PC, despite a similar fatty acid pattern(10).
Milk-PL at a dose of 0·5 or 1·2 % decreased plasma choles-
terol in mice on a high-fat diet(11,12) but not on a regular-fat
chow diet(11). Recently published well-designed human studies
found no effect of milk-PL on plasma lipids(13,14), but a signiﬁ-
cant effect of PL-rich buttermilk(15), a favourable trend of
buttermilk combined with egg yolk as compared with egg
alone(16), and of milk fat with intact MFGM as compared
with pure milk fat(17).
Metabolic effects of PL go beyond those on cholesterol
absorption and plasma lipids (for a review, see Kullenberg
et al.(18)). In mouse or rat experimental models, soya-PL(19),
as well as milk-PL(11,12,20) and SM(21) decreased liver lipids.
An SM-supplemented diet increased hepatic gene expression
of PPARα, and decreased expression of stearoyl-CoA
desaturase-1 (SCD1) in Zucker fatty rats(21). Also, mice on a
high-fat milk-PL-enriched diet showed reduced hepatic
expression of SCD1 and fatty acid synthase genes(11). Lower
SCD1 activity is linked to improved liver lipid metabolism
and insulin sensitivity(22).
PC and SM are important dietary sources of choline. The
European Food Safety Authority has approved claims for diet-
ary choline with respect to lipid metabolism, liver function and
homocysteine (Hcy) metabolism(23). The Institute of Medicine
considers 550 mg/d choline as adequate intake for men(24).
Most subjects on an experimental choline-deﬁcient diet devel-
oped fatty liver, experienced muscle damage, or both, within a
few weeks(25). Choline metabolism, methionine metabolism
and folate metabolism are interrelated. The dietary require-
ment for choline varies substantially among individuals, and
is modulated by SNP in genes of choline and folate metabol-
ism(26), including methylenetetrahydrofolate reductase
(MTHFR)(27,28).
Based on the hypothesis that PL are relevant for the bene-
ﬁcial health effects of dairy products(29), we studied the meta-
bolic effects of milk-PL. The ﬁrst study assessed the metabolic
effects of milk-PL as compared with the same amount and
pattern of fatty acids provided as milk fat. In a second step
the effects of milk-PL were compared with those of
soya-PL, i.e. PL with both a different PL class pattern and a
different fatty acid pattern. The main focus of these studies
was on the treatment effects on the total cholesterol (TC):
HDL-C ratio. The TC:HDL-C ratio allows the best prediction
of future coronary events, closely followed by the apoB:apoA1
ratio(30). In order to cover further parameters relevant to CVD
risk, plasma parameters of lipid and carbohydrate metabolism,
various inﬂammation markers, total Hcy (tHcy) and liver
enzyme activities were measured. Furthermore, the poly-
morphism MTHFR 677, which may affect choline and betaine
metabolism, respectively, was determined, as a potential genet-
ic determinant affecting PL bioactivity.
Subjects and methods
Subjects
Participants were recruited through the Max Rubner-Institut
database and local advertisements in Karlsruhe and the sur-
rounding area, Germany. Men were eligible if between 50
and 76 years of age, overweight (BMI ≥ 27 kg/m2) and non-
smokers. Exclusion criteria for both trials were the use of
drugs affecting lipid metabolism, acute or chronic gastrointes-
tinal diseases (e.g. diseases affecting nutrient absorption, diges-
tion, metabolism or excretion), diabetes (fasting glucose ≥7·0
mmol/l), milk protein allergy or lactose intolerance, and fur-
thermore soya protein allergy in trial 2. The studies were con-
ducted according to the guidelines laid down in the
Declaration of Helsinki and all procedures involving human
subjects were approved by the ethics committee of the State
Medical Chamber of Baden-Württemberg (F 2010-020 and
F 2010-089). Written informed consent was obtained
from all subjects prior to the studies. The studies were
registered at https://drks-neu.uniklinik-freiburg.de/drks_web as
DRKS00000383 (trial 1) and DRKS00003125 (trial 2).
Participants were asked to consume no more than one alcoholic
drink per d, and not to change their eating habits and physical
activity routine during the trials. The use of supplemental vitamins,
minerals, phytochemicals or n-3 oil supplements was forbidden. A
list of products which should be avoided was provided. The sub-
jects were requested to inform the study physician about any newly
prescribed medications.
Test materials
Milk-PL preparations (Lipamin M20; Lecico) were isolated from
butter serum. PL were quantiﬁed by 31P-NMR-spectroscopy
(Spectral Service). The Lipamin M20 lot used for trial 1 con-
tained 18·4 % PL, 31·6 % total fat, 51·6 % protein and 5·4 %
lactose. The lot used for trial 2 contained 31·2 % PL, 41·2
% total fat, 46·0 % protein and 1·2 % lactose. PC and SM
represented 29·2 and 23·1 % of total PL in the lot for trial
1 and 29·5 and 25·1 % in the lot for trial 2. The soya-PL prep-
aration (deoiled soya lecithin P 900 IPM; Lecico) used for trial
2 contained 91 % total fat and 72 % PL according to the
manufacturer, but only 66·1 % PL as later determined by
31P-NMR-spectroscopy. PC represented 34·7 % of the total
soya-PL.
Study design trial 1
This trial was performed in spring 2010 in a randomised,
double-blind and parallel design. Eligible participants were
randomly assigned following simple randomisation procedures
(computerised random numbers between 0 and 1) to one of
2
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two treatment groups. In all, seventy-six men were screened
for participation; sixty-three were included in the study. One
dropped out when he started to use non-permitted medica-
tion, so sixty-two men completed the trial. During the
8-week intervention the participants consumed daily 200 ml
of PL-enriched drink (containing 2 g milk-PL) or 200 ml of
control drink (containing 2 g milk fat). The PL-drink was
semi-skimmed milk (1·5 % fat) supplemented with 5·4 %
Lipamin M20 powder (Lecico). To make up for protein, lac-
tose and lipids of the Lipamin M20 powder, the control
drink was prepared by enriching semi-skimmed milk with
cream and skimmed milk concentrate. Composition of both
test drinks is described in Table 1. They were manufac-
tured and bottled in enhanced shelf-life quality packaging
(Unternehmensgruppe Theo Müller). Fresh batches were pro-
vided and picked up by the participants every 2 weeks. Drinks
were stored refrigerated until consumption. Appearance, taste
and packaging of the drinks were identical and bottles (200 ml
volume) were coded in such a way that participants and staff
were unaware of the drink allocation. Participants were
asked to consume the drinks with a meal.
Study design trial 2
This trial was performed in spring 2011. Of the seventy-one
men screened for participation, ﬁfty-eight were included in
the study. One man in the milk-PL group dropped out
because of suspected allergic reactions, so ﬁfty-seven men
completed the trial. Thirty-eight of these men also had partici-
pated in trial 1. During the 7-week intervention the partici-
pants consumed daily 250 ml of test drink that provided
either 3 g milk-PL or 2·8 g soya-PL. The drink was semi-
skimmed milk (1·5 % fat) supplemented with 3·85 %
Lipamin M20 powder or 1·67 % soya lecithin (P 900 IBM)
(both Lecico). Calculation of the soya-PL supplemental dose
was based on the manufacturers’ data, to yield 3 g per 250
ml. However, based on the 31P-NMR-spectroscopy data, the
ﬁnal PL concentration was somewhat lower, namely 2·8 g
per 250 ml. Milk drinks for this study were manufactured
and bottled in ultra-high temperature treatment (UHT) quality
packaging (Milchwerke Mittelelbe) and handed out to the par-
ticipants at the start of the trial. Drinks were identical in
appearance and taste. Bottles (250 ml volume) were coded.
Again, participants were asked to consume the drinks with a
meal.
Diet protocols
Participants completed 4-d food protocols (according to
Koebnick et al.(31), with minor modiﬁcations) during and outside
the intervention periods. Nutrient intake analysis was done
using PRODI 5.7 software and Bundeslebensmittelschlüssel
(BLS) version II.3 (trial 1), or Prodi® version 5.9 and BLS ver-
sion 3.0 (trial 2). Calculation of PL intake was based on
recorded food items and PL concentrations reported in the lit-
erature. As there were only few data available, the calculated
values can give only a rough approximation of the true intake.
The USDA nutrient database 2004 for choline (https://
www.ars.usda.gov/SP2UserFiles/Place/80400525/Data/
Choline/Choln02.pdf) was used to estimate choline intake.
Blood sampling
Fasting venous blood samples were collected before starting
the intervention (day zero) and after the intervention, between
07.30 and 10.00 hours. EDTA whole blood (for glutathione
determination and DNA preparation), plasma (EDTA, lithium
heparin) and serum samples were obtained. When required,
samples were stored frozen at −80°C until analysis.
Anthropometric and blood pressure measurements
Anthropometric measures including waist and hip circumfer-
ences and blood pressure measurements were taken at the
beginning and at the end of the intervention periods and
recorded following standard operation procedures according
to WHO 2008(32). BMI was calculated by dividing body
mass (in kg) by height squared (in m). Bioelectrical impedance
analysis (SensorMedics) was used to determine percentage of
body fat.
Analytical methods
Fasting plasma or serum samples were analysed for routine
clinical parameters as well as concentrations of TAG, TC,
HDL-C and LDL-cholesterol (LDL-C), glucose, and
γ-glutamyl transferase (GGT) and aspartate transaminase
(AST) activities on the same day by an accredited routine
laboratory (MVZ Labor Seelig). ApoA1, apoB and alanine
Table 1. Composition of the test drinks*
Trial 1 Trial 2
Control Milk-PL Soya-PL Milk-PL
Milk (1·5 % fat)
supplemented
with. . .
Cream 4·7
%, SMC
(10·6 %)†
Lipamin
M20
(5·4 %)‡
P 900
IBM
(1·67 %)
Lipamin
M20
(3·85 %)‡
Chemical composition
Fat (%) 3·4 3·2 2·5 2·6
Protein (%) 4·3 5·7 3·4 5·0
Lactose (%) 6·2 4·8 4·4 4·5
DM (%) 14·6 14·9 11·7 13·7
Ca (%) 0·186 0·173 0·123 0·137
Absolute amounts provided per d with the test drinks
Volume (ml) 200 200 250 250
Fat (g) 6·8 6·4 6·3 6·4
PL (g)§ 0·0 2·0 2·8 3·0
Choline (mg)§‖ 0 164 156 264
Energy (kJ)¶ 623 604 577 659
PL, phospholipid; SMC, skimmed milk concentrate.
* Chemical analysis was done after blending the carrier milk with supplements. For
trial 1, values are the mean of four batches, each determined in triplicate.
† Cream with 39 % fat and SMC with 35 % DM, 0·26 % fat.
‡ Lipamin M20 lot 1 and lot 2, respectively.
§ Values for supplements only. Concentrations in the milk used for the test drinks
(approximately 0·029 g/100 g PL and 16·1 mg/100 g choline) not included.
‖ Choline supply is calculated from phosphatidylcholine and sphingomyelin concen-
trations in the supplements.
¶ Calculated value.
3
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transaminase (ALT) activity were assessed enzymatically using
the Konelab 20i clinical analyser (Thermo Scientiﬁc). Total
glutathione in whole blood was measured according to
Becker et al.(33). Serum concentrations of insulin and high-
sensitivity C-reactive protein (CRP) were measured by
ELISA (DRG Instruments) as well as soluble intracellular
adhesion molecule and IL-6 (R&D Systems). Serum PL
were analysed by an enzymic assay (WAKO Chemicals).
Plasma tHcy concentrations were assessed by HPLC with
ﬂuorimetric detection according to Toyo’oka & Imai(34).
Homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as ((fasting insulin mU/l × fasting
glucose mmol/l)/22·5) according to Matthews et al.(35). For
determination of the MTHFR 677 genotype (rs1801133), per-
ipheral blood mononuclear cell genomic DNA was prepared
using a microspin kit (NucleoSpin blood; Macherey-Nagel)
and further processed utilising a PCR-based high-resolution
melting curve analysis method carried out on a LightCycler®
480 instrument with subsequent data processing by gene scan-
ning software (Roche). The respective PCR primer (5′→3′)
sequences were: (forward) >>ccc aaa ggc cac ccc gaa gc<<
and >>gcc cat gtc ggt gca tgc ct<< and the according PCR
protocol consisted of thirty-nine cycles of denaturation,
annealing and extension (95°C, 10 s; 60°C, 15 s; 72°C, 1 s)
and a subsequent melting analysis.
Statistical analysis
A previous study providing 2·8 or 5·8 g/d PL(6) suggested that
a PL-induced 6 % decrease in the TC:HDL-C ratio is realistic.
Based on another study showing a 0·29 mmol/l (6·3 %)
decrease in the TC:HDL-C ratio along with a standard devi-
ation of 0·45 mmol/l in response to dietary modiﬁcation,
and with a baseline TC:HDL-C ratio of 4·5(36), similar to
that in our participants, the required total number of partici-
pants completing the study was calculated as n 58 (α = 0·05
two-tailed, power = 90 %). Data are expressed as mean and
standard deviation. Data were tested for normality (Shapiro–
Wilk) and variance homogeneity (Levene). Intervention effects
were analysed by repeated-measures ANOVA if datasets were
normally distributed and showed variance homogeneity. For
datasets with asymmetric distribution delta concentrations
were compared by t test or Mann–Whitney rank-sum test.
Changes of tHcy concentration as a function of MTHFR
677 genotype (CC v. CT and TT combined) were assessed
by the Kruskal–Wallis H test. Analyses were carried out
using SPSS Inc. PASW 17 software. The level of signiﬁcance
was set at P < 0·05.
Results
Baseline characteristics
Baseline characteristics of the participants who completed
trials 1 and 2 are presented in Table 2. Participants were either
overweight (40·3 % in trial 1 and 56·1 % in trial 2) or obese
(59·7 % in trial 1 and 43·9 % in trial 2) and all had increased
waist circumference, body fat mass and TC concentration.
Baseline parameters were not signiﬁcantly different between
the two groups within each trial, and similar between trials 1
and 2 (Table 2). The distribution of the MTHFR 677 genotype
in trial 2 was CC (n 23; 40·4 %), CT (n 32; 56·1 %) and TT
(n 2; 3·5 %).
Dietary intake and compliance
Energy intake and nutrient composition of the habitual diets
during the intervention periods of trials 1 and 2 are given in
Table 3. Carbohydrate and energy intakes was slightly higher
in the soya-PL as compared with the milk-PL group in trial 2
(P < 0·05). Otherwise there were no differences between
intervention groups, and there were no signiﬁcant differences in
energy and nutrient intakes during the intervention and outside
the intervention period in both studies. Nutrient intake was com-
parable with that of the German average population of that age
group as assessed in the Nationale Verzehrstudie II (2008)
(https://www.bmel.de/SharedDocs/Downloads/Ernaehrung/
NVS_ErgebnisberichtTeil2.pdf?__blob=publicationFile). Major
sources of PL in foods were meat and meat products (41·9
and 41·7 %, respectively) and egg and egg products (30·3 and
Table 2. Baseline characteristics of the participants
(Mean values and standard deviations)
Trial 1 (n 62) Trial 2 (n 57)
Variable Mean SD Mean SD
Age (years) 62·5 6·4 63·1 6·5
Weight (kg) 94·5 10·2 93·3 9·7
BMI (kg/m2) 30·8 2·4 30·4 2·4
Waist circumference (cm) 109·6 7·2 108·2 6·4
Body fat mass (%) 31·0 2·5 31·1 2·9
Total cholesterol (mmol/l) 5·87 0·89 5·60 0·88
HDL-cholesterol (mmol/l) 1·37 0·34 1·31 0·30
TAG (mmol/l) 1·44 0·66 1·49 0·55
Glucose (mmol/l) 5·50 0·57 5·44 0·54
ApoA1 (g/l) 1·60 0·23 1·62 0·21
ApoB (g/l) 1·27 0·25 1·37 0·21
Table 3. Energy and nutrient intakes during the intervention periods*
(Mean values and standard deviations of 4-d protocols)
Trial 1 (n 62) Trial 2 (n 57)
Mean SD Mean SD
Energy (MJ/d) 9·49 2·18 9·57† 1·99
Protein (% energy) 17·9 4·0 17·4 4·3
Fat (% energy) 36·1 11·7 34·9 8 4·8
Carbohydrates (% energy) 44·1 11·3 45·8† 9·8
Mono-/disaccharides (% energy) 19·6 7·6 20·1 7·6
Dietary fibre (g/d) 27·1 8·1 25·4 7·8
Cholesterol (mg/d) 421 152 444 227
Ca (mg/d) 991 332 924 270
Vitamin B6 (mg/d) 1·9 0·5 1·9 0·5
Folate (μg/d) 280 86 355 151
Vitamin B12 (μg/d) 7·7 4·3 8·2 7·5
Phospholipids (g/d) 3·08 1·28 3·00 1·75
Choline (mg/d) 384 117 387 156
* All foods including carrier milk, excluding supplements.
† Energy and carbohydrate intakes were 9·7 and 12 % higher in the soya-
phospholipid group as compared with the milk-phospholipid group in trial 2
(P = 0·049 and 0·035, respectively).
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29·2 %, respectively). Choline intake was similar to that of US
populations(37). Major sources of choline were also meat and
meat products (34·3 and 33·0 %, respectively) and egg and egg
products (18·5 and 17·9 %, respectively), closely followed by
the food group bread, pastries and grain products (16·6 and
16·4 %, respectively).
Participants consumed the test drinks in addition to the nor-
mal diet. Test drinks were well tolerated. Subjects did not
report side effects, except for one person in trial 2. There
were no objective chemical measures (blood parameters) avail-
able to assess compliance. But as participants kept in regular
contact with the study centre, and on the basis of the dietary
records provided, appropriate compliance was assumed.
Intervention effects trial 1
Milk-PL as compared with control did not change the lipid
parameters, namely TC, HDL-C, LDL-C, TAG, PL, the pri-
mary parameter TC:HDL-C ratio as well as apoA1 and
apoB. Likewise, concentrations of glucose, insulin and
HOMA-IR did not change (Table 4). Milk-PL as compared
with the control treatment did not change concentrations of
CRP, IL-6, soluble intracellular adhesion molecule as well as
tHcy (Table 4). Due to technical problems, valid glutathione
data were only available at the end of the intervention.
Values did not differ between groups (0·81 (SD 0·29) v. 0·80
(SD 0·24) mmol/l whole blood) for the control and milk-PL
groups, respectively. Concerning liver enzyme activities, there
were no signiﬁcant intervention effects on ALT and AST.
There was a signiﬁcant 16 % increase of GGT activity in the
control group (P < 0·001), but no change in the milk-PL
group, and thus a signiﬁcant intervention effect (P < 0·001)
(Table 4). However, enzyme activities remained in their normal
reference ranges. Milk-PL as compared with control fat did
not change body weight and BMI during the 8-week interven-
tion. There was a small yet signiﬁcant decrease in waist
circumference.
Intervention effects trial 2
Milk-PL as compared with soya-PL did not change the lipid
parameters, namely TC, HDL-C, LDL-C, TAG, PL, the pri-
mary parameter TC:HDL-C ratio as well as apoA1 and
apoB. Furthermore, glucose, insulin and HOMA-IR did not
change. Of the inﬂammation parameters, IL-6 increased in
both the milk-PL and soya-PL groups, with no intervention
effect. There were no signiﬁcant changes in CRP, soluble intra-
cellular adhesion molecule, glutathione and tHcy concentra-
tions. Subjects with a mutation in MTHFR 677 (CT and
TT) (thirty-four participants) showed an 11 % higher baseline
plasma tHcy concentration than those with the wild-type CC
(twenty-three participants) (P < 0·05). Statistical analysis
showed that MTHFR genotype did not modulate the effect
of the PL-intervention on plasma tHcy (data not shown).
Further, the activity of ALT and AST was also unaffected
by intervention. There was a signiﬁcant intervention effect
on GGT activity (P < 0·05), in that activity was slightly
increased in the soya-PL group and slightly decreased in the
milk-PL group (Table 5). No changes were observed in
anthropometric measures and blood pressure.
Discussion
Milk-PL and soya-PL intakes did not change lipid and apolipo-
protein concentrations in our trials. In other well-designed
human studies the effect of milk-PL was also moderate or
non-existent. The consumption of a drink with 2·8 g/d of
milk-PL (rich in SM) as compared with a control drink con-
taining the same amount of PL low in SM (66 % egg-PL)
for 3 weeks did not signiﬁcantly change the concentrations
of TC, LDL-C, HDL-C, TAG, apoA1 and apoB(14). In sub-
jects with atopic dermatitis, 3 g/d milk-PL did not improve
TC, LDL-C, HDL-C or TAG(13). In a short pilot study, 1
g/d of milk-SM increased HDL-C by approximately 13 %,
but did not change the TC:HDL-C ratio(38). However, in par-
ticipants who consumed a drink providing either 45 g/d of
MFGM-rich buttermilk solids (188 mg/d PL) or 45 g/d of a
macro-/micronutrient-matched dairy placebo for 4 weeks,
the buttermilk as compared with the control drink reduced
TC and LDL-C by 3·1 %, and TAG by 10·7 %(15). In another
study the participants were randomised to one of three dietary
regimens, either to no change in the dietary habits (control) or
one extra egg per d or 100 ml buttermilk (approximately 90
mg PL per d) together with one egg yolk per d for 12
weeks. In female subjects the regular egg consumption
increased TC and LDL-C as compared with the control
group, while no such increase was observed in the butter-
milk–egg yolk group. Similarly, milk fat with intact MFGM
structures (41·8 g fat/d, 19·8 mg PL/d) did not increase TC
and LDL-C in human subjects, while the same amount of
pure butter oil did so. Furthermore, suppression of a number
of genes in peripheral blood mononuclear cells was correlated
with changes in lipids(17).
Our subjects were somewhat older and more overweight than
those of other studies examining the effect of milk-PL(13–17) or
pure milk-SM(38), had higher plasma TAG concentrations and
somewhat or clearly higher TC:HDL-C ratios. Baumgartner
et al.(16) observed a protective effect of milk-PL only in females,
but other studies using milk-PL(14,15) or milk-SM(38), as well as
studies using soya-PL(6,7,39) gave little indication that males and
females respond differently.
Our trials, like two others(13,14), used milk-PL concentrates
isolated from butter serum as test material, while again others
used buttermilk(15,16) or cream with MFGM(17). An in vitro pre-
cursor study suggested that extensive processing may impair
the cholesterol-lowering activity of MFGM from buttermilk,
possibly through proteins adsorbing at the surface of
MFGM fragments(40). Concentrated isolated MFGM material
may thus have differing structural properties than liquid
forms in buttermilk or cream, which may in turn affect lipid
metabolism differently(41). It is a tempting speculation that
this difference in the food matrix may have contributed to
the lack of effect in our study and others(13,14). But there is
no basis for such an assumption without further appropriate
experiments. An alternative explanation would be that other
components than PL in buttermilk may contribute to the
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effects. Buttermilk is usually fermented and contains lactic acid
bacteria. Some of them were reported to affect lipid
metabolism(42).
In trial 1 milk-PL reduced waist circumference slightly yet
signiﬁcantly. However, there was no such effect compared
with soya-PL in trial 2. Blood pressure did not change in either
trial. In the study of Conway et al.(43) a buttermilk supplement
reduced systolic blood pressure and also decreased concentra-
tion of the angiotensin I-converting enzyme in normotensive
subjects. The authors attributed these effects to the proteins
of MFGM, as there is evidence that milk peptides can reduce
blood pressure (for a review, see Conway et al.(43)). Beneﬁcial
effects of dairy product intake on body weight and body com-
position are often attributed to the Ca content(44), but also to
proteins in milk and milk products(45).
The only parameters of liver function determined in our
study were liver enzyme activities in serum. Elevated liver
enzyme activities, in particular ALT and GGT, are indicators
of fatty liver. We observed a reduced GGT activity in the
milk-PL group as compared with the control group in trial
1, and there was also a reduced activity in the milk-PL
group as compared with the soya-PL group in trial 2. Yet all
enzyme activities remained within the normal physiological
range, and the fatty liver index did not change. ALT, AST
or GGT activities were not modiﬁed by buttermilk PL in
one study(16), or were not examined at all in other
studies(13–15,43).
As mentioned before, PL and SM are a source of choline,
and may affect liver function also via their role in choline
metabolism. As little as 300 mg supplemental choline/d was
sufﬁcient to avoid increased serum ALT, AST or GGT activ-
ities(28). The majority of our subjects consumed more than this
amount. Rat or mouse experiments, which demonstrated
decreased AST and ALT activities(19) or decreased liver lipids
following a diet with supplemental soya-PL(19),
milk-PL(11,12,20) or SM(21), were performed in animals with
enhanced susceptibility due to either genetic disposition(12,21)
or diets high in ethanol or fat(11,19,20). Milk-PL supplements
had no effects on liver lipids in rats on a normal chow diet(11).
Choline plays a pivotal role as a methyl donor for the
remethylation of Hcy to methionine. Moderately elevated con-
centrations of plasma tHcy have been linked to a variety of dis-
ease conditions, including CVD. Higher choline plus betaine
intakes (within the normal range) were associated with moder-
ately lower plasma tHcy concentration as well as lower concen-
trations of inﬂammatory markers like IL-6 and TNF-α in an
Table 4. Intervention effects of trial 1
(Mean values and standard deviations)
Control (n 31) Milk-PL (n 31)†
Day 0 Day 56 Day 0 Day 56
Mean SD Mean SD Mean SD Mean SD P*
Anthropometric measures and blood pressure
Body weight (kg) 94·7 12·6 94·5 12·2 94·2 7·4 93·3 7·7 0·181
BMI (kg/m2) 30·9 2·9 30·8 2·8 30·7 1·9 30·4 2·0 0·138
Waist circumference (cm) 109·0 8·1 109·1 8·3 110·2 6·1 108·8 6·2 0·001
Body fat mass (%) 30·8 2·4 30·3 2·6 31·2 2·6 30·9 2·8 0·753
Systolic BP (mmHg) 131·7 17·2 131·7 16·4 139·6 21·6 135·3 19·1 0·132
Diastolic BP (mmHg) 82·7 8·9 82·6 8·9 86·4 10·6 84·0 11·0 0·174
Glucose and insulin sensitivity
Glucose (mmol/l) 5·51 0·47 5·35 0·43 5·49 0·66 5·42 0·63 0·334
Insulin (pmol/l) 104·4 51·3 107·8 98·9 89·2 52·7 92·7 54·4 0·795
HOMA-IR 3·74 2·03 3·74 3·72 3·20 2·06 3·30 2·16 0·495
Plasma lipids and apolipoproteins
TC (mmol/l) 5·70 0·94 5·72 1·03 6·03 0·82 5·90 1·04 0·302
LDL-C (mmol/l) 3·58 0·76 3·69 0·81 3·78 0·82 3·84 0·89 0·765
HDL-C (mmol/l) 1·32 0·34 1·30 0·28 1·43 0·33 1·42 0·37 0·290
TC:HDL-C ratio 4·50 1·05 4·56 1·20 4·46 1·23 4·40 1·22 0·533
TAG (mmol/l) 1·41 0·49 1·70 1·07 1·46 0·80 1·50 0·64 0·627
PL (mmol/l) 1·88 0·26 1·93 0·37 2·03 0·32 1·97 0·32 0·091
ApoA1 (g/l) 1·56 0·24 1·56 0·22 1·64 0·21 1·61 0·23 0·057
ApoB (g/l) 1·25 0·23 1·26 0·22 1·28 0·27 1·27 0·25 0·571
Biomarkers of inflammation and liver function
CRP (mg/l) 2·19 2·32 1·42 1·30 2·53 3·03 1·75 1·47 0·947
sICAM (ng/ml) 191·1 31·5 187·6 29·1 189·9 29·3 183·6 25·2 0·426
IL-6 (pg/ml) 1·62 1·48 1·21 0·43 1·34 0·77 1·18 0·54 0·134
Homocysteine (μmol/l) 11·7 3·2 11·8 3·0 11·6 4·0 12·0 3·9 0·547
ALT (U/l) 18·0 8·6 20·9 10·5 17·5 9·9 17·3 7·8 0·057
AST (U/l) 26·2 7·3 25·1 6·2 25·0 7·1 23·5 6·7 0·296
GGT (U/l) 37·1 16·0 43·9 22·8 34·3 15·5 33·2 14·1 <0·001
Milk-PL, milk phospholipids; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; LDL-C, LDL-cholesterol; HDL-C,
HDL-cholesterol; PL, phospholipids; CRP, C-reactive protein; sICAM, soluble intracellular adhesion molecule; ALT, alanine transaminase; AST, aspartate transaminase; GGT,
γ-glutamyl transferase.
* P for intervention effect (time × group). Parameters were not significantly different between the control and milk-PL groups at the start of the trial.
† n 30 for IL-6.
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observational study(46). A high choline supplement attenuated
the post-methionine load-induced increase in plasma tHcy(28),
while a choline-deﬁcient diet increased plasma tHcy(25).
Participants in our trials had a choline intake comparable
with or even higher than the cohort of Detopoulou et al.(46),
but intake of PL and choline was highly variable between par-
ticipants. Considering that also individual requirements are
variable(26), it is not surprising that the additional choline pro-
vided by the soya-PL or milk-PL supplements did not modify
the concentration of tHcy or inﬂammatory parameters.
MTHFR 677 genotype may modify plasma tHcy. Baseline
plasma tHcy concentrations were modestly higher in men
with the MTHFR 677TT relative to men with the 677CC
genotype, and increased more strongly in response to low fol-
ate intake(27). A post-methionine load-induced increase of
plasma tHcy was less pronounced in men with the MTHFR
677TT than in those with the 677CC genotype(28). We
observed only small yet signiﬁcantly higher baseline plasma
tHcy concentrations in men with the MTHFR 677CT than
in those with the 677CC genotype in trial 2. Yet the group
size for genotyping was small. Furthermore, in this study
almost only 677CT heterozygotes rather than 677TT
homozygotes were compared with 677CC homozygotes.
Genetic analyses took place after the study had been per-
formed and with knowledge about the general results of the
analyses. Anyhow, the genotype did not modulate any inter-
vention effect. Strengths of this study are the well-
characterised test material with a closely matched control,
the fairly long intervention periods, and the well-documented
dietary habits. Potential limitations are variability of dietary
habits and thus background diet and further lifestyle factors,
including physical activity. Furthermore, only middle-aged
overweight male volunteers were included in the studies. In
conclusion, under these conditions dietary supplementation
with milk-PL as compared with control milk fat reduced
waist circumference and, as compared with both control fat
and soya-PL, GGT activity.
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Table 5. Intervention effects of trial 2
(Mean values and standard deviations)
Soya-PL (n 29) Milk-PL (n 28)
Day 0 Day 49 Day 0 Day 49
Mean SD Mean SD Mean SD Mean SD P*
Anthropometric measures and blood pressure
Body weight (kg) 91·0 8·6 91·1 8·9 95·6 10·4 95·4 10·3 0·654
BMI (kg/m2) 30·2 2·6 30·0 2·8 30·6 2·3 30·6 2·3 0·444
Waist circumference (cm) 107·3 6·6 107·7 6·8 109·1 6·2 109·4 6·4 0·816
Body fat mass (%) 30·9 2·5 30·5 2·4 31·2 3·3 30·5 2·8 0·395
Systolic BP (mmHg) 144·1 18·6 143·9 16·6 139·6 17·5 140·1 19·8 0·829
Diastolic BP (mmHg) 91·2 8·6 91·3 7·8 91·0 11·7 92·3 12·7 0·346
Glucose and insulin sensitivity
Glucose (mmol/l) 5·44 0·50 5·33 0·36 5·44 0·59 5·20 0·57 0·254
Insulin (pmol/l) 81·9 33·2 88·8 28·0 80·5 56·4 79·7 42·7 0·609
HOMA-IR 2·89 1·27 2·75 0·97 2·77 1·80 2·65 1·45 0·492
Plasma lipids and apolipoproteins
TC (mmol/l) 5·46 0·84 5·38 0·77 5·74 0·92 5·65 1·02 0·573
LDL-C (mmol/l) 3·58 0·69 3·65 0·63 3·84 0·76 3·80 0·87 0·372
HDL-C (mmol/l) 1·31 0·32 1·31 0·27 1·32 0·28 1·37 0·28 0·193
TC:HDL-C ratio 4·35 1·04 4·22 0·80 4·46 0·78 4·22 0·83 0·234
TAG (mmol/l) 1·47 0·67 1·55 0·54 1·50 0·57 1·51 0·53 0·632
PL (mmol/l) 2·19 0·36 2·22 0·35 2·24 0·33 2·27 0·41 0·942
ApoA1 (g/l) 1·61 0·22 1·59 0·20 1·63 0·20 1·63 0·22 0·516
ApoB (g/l) 1·33 0·22 1·35 0·20 1·41 0·20 1·38 0·25 0·249
CRP (mg/l) 2·43 2·09 2·80 2·75 2·62 2·59 2·17 1·70 0·576
Biomarkers of inflammation and liver function
sICAM (ng/ml) 211·2 34·8 205·5 36·7 199·3 37·7 197·3 35·1 0·449
IL-6 (pg/ml) 1·58 0·86 1·74 1·16 1·33 0·77 1·45 0·65 0·151
Homocysteine (μmol/l) 13·9 5·0 13·7 4·7 12·5 4·0 12·4 3·5 0·962
Glutathione (mmol/l WB) 0·67 0·13 0·69 0·14 0·70 0·15 0·71 0·16 0·714
ALT (U/l) 13·9 5·2 15·9 6·9 12·0 4·9 13·2 6·6 0·615
AST (U/l) 25·3 5·5 26·1 5·6 24·9 6·4 25·3 7·9 0·442
GGT (U/l) 36·5 15·6 37·9 16·9 33·4 15·4 32·0 13·0 0·042
Soya-PL, soyabean phospholipids; milk-PL, milk phospholipids; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; LDL-C,
LDL-cholesterol; HDL-C, HDL-cholesterol; PL, phospholipids; CRP, C-reactive protein; sICAM, soluble intracellular adhesion molecule; WB, whole blood; ALT, alanine transamin-
ase; AST, aspartate transaminase; GGT, γ-glutamyl transferase.
* P for intervention effect (time × group). Parameters were not significantly different between the soya-PL and the milk-PL groups at the start of the trial.
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